<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; Dendreon investors.</title>
	<atom:link href="http://www.psa-rising.com/blog/tag/dendreon-investors/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Tue, 16 Aug 2011 09:39:00 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Provenge Profit Taking</title>
		<link>http://www.psa-rising.com/blog/2007/05/provenge-profit-taking/</link>
		<comments>http://www.psa-rising.com/blog/2007/05/provenge-profit-taking/#comments</comments>
		<pubDate>Fri, 11 May 2007 23:01:02 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Dendreon investors.]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/05/11/provenge-profit-taking</guid>
		<description><![CDATA[Dendreon&#8217;s CEO Mitchell Gold traded some of his stock during the high period following the FDA Advisory panel vote on his company&#8217;s prostate cancer immunotherapy sipuleucal-T (Provenge). Gold told the WSJ Health blog that he sold &#8220;less than 20%&#8221; of his holdings in the company following the upbeat FDA advisory panel vote. &#8220;it&#8217;s all public,&#8221; [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/05/provenge-profit-taking/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Forbes View of Provenge</title>
		<link>http://www.psa-rising.com/blog/2007/04/forbes-view-of-provenge/</link>
		<comments>http://www.psa-rising.com/blog/2007/04/forbes-view-of-provenge/#comments</comments>
		<pubDate>Sat, 21 Apr 2007 21:20:59 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Dendreon investors.]]></category>
		<category><![CDATA[Forbes]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/04/21/forbes-view-of-provenge/</guid>
		<description><![CDATA[Reviewing Proveng&#8217;s chances of FDA approval from the point of view of investors, Matthew Herper gives an overview useful for patients as well. Herper writes: The FDA has a legal deadline of May 15 to make a decision&#8211;although it is possible to break or extend it. But buying the stock in front of this deadline [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/04/forbes-view-of-provenge/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

